Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immunotech Biopharm Ltd ( (HK:6978) ) just unveiled an announcement.
Immunotech Biopharm Ltd announced that all proposed resolutions at its Annual General Meeting held on May 23, 2025, were passed unanimously by shareholders. The resolutions included the adoption of financial statements, re-election of directors, and authorization for the board to manage share allotments. This outcome reflects strong shareholder support and positions the company for continued strategic governance and operational stability.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on the development and commercialization of innovative therapies, primarily targeting cancer and autoimmune diseases.
Average Trading Volume: 722,000
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.77B
For detailed information about 6978 stock, go to TipRanks’ Stock Analysis page.